Merrill keeps Amylin at neutral

Amylin Pharmaceuticals Inc. was maintained at neutral by Merrill Lynch analyst Tom McGahren on news that Amylin and Lilly have asked physicians to limit new patient starts for Byetta due to supply issues with the cartridge used to administer the drug. The slowing momentum of the launch is seen as a short-term problem by Merrill and easily solved when a second supplier comes on line in the third quarter. Shares of the San Diego-based biopharmaceutical company were down 74 cents, or 1.73%, at $42.07 on volume of 3,337,053 shares versus the three-month running average of 2,654,220 shares. (Nasdaq: AMLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.